Modulators of the Human Voltage-Gated Proton Channel H_v1.

Area of Science:

• Biophysics
• Molecular Biology
• Oncology

Background:

• The voltage-gated proton channel (Hv1) facilitates proton (H+) transport across cell membranes, driven by membrane potential.
• Hv1 functions as a dimer, utilizing its voltage-sensing domain (VSD) and a hydrogen-bond network for proton conduction, distinct from traditional ion channels.
• Hv1 is expressed in diverse human cells, including immune cells, sperm, and notably, tumor cells, where it plays a role in adapting to the tumor microenvironment.

Purpose of the Study:

• To explore the role of Hv1 in cancer cell adaptation and its potential as a therapeutic target.
• To review known modulators of Hv1, categorizing them into inhibitors and activators.
• To highlight the therapeutic potential of targeting Hv1 in various diseases, including cancer and inflammation.

Main Methods:

• Literature review and analysis of existing research on Hv1 structure, function, and expression.
• Examination of the role of Hv1 in cellular physiology, particularly in tumor cells under hypoxic or ROS-producing conditions.
• Categorization and discussion of known Hv1 inhibitors and activators based on published data.

Main Results:

• Hv1 rapidly removes acidic intermediates from the cytosol of tumor cells, aiding their survival and progression in the tumor microenvironment.
• A variety of molecules, including ions, small molecules, lipids, and peptides, act as Hv1 inhibitors, while fewer activators like albumin and quercetin are known.
• Hv1 modulation significantly impacts cellular physiology, especially under pathological conditions such as cancer and inflammation.

Conclusions:

• Hv1 is a promising diagnostic marker and therapeutic target in oncology due to its role in tumor cell adaptation.
• Targeting Hv1 with selective inhibitors or activators presents a potentially effective therapeutic strategy for cancer and inflammatory diseases.
• Further research into Hv1 modulators and their mechanisms of action is warranted for clinical applications.